Articles On Imugene (ASX:IMU)

The S&P/ASX 300 Index (ASX: XKO) is charging higher today following a mixed daily movement throughout the week. At the time of writing, the ASX 300 is up 0.74% to 7,477 points. This means that over the past month, the index is now hove...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week The Healthc...

There was broad based selloff across ASX blue chips today, with all 11 sectors falling into the red. The benchmark ASX 200 index ended up lower by 1.9% as it sank further from the mid session loss of 1%. It was one of the biggest drops for...

Highlights The Australian share market is expected to fall again on Thursday after US and European equities witnessed their worst one-day rout in three weeks. The ASX 200 may open the day 27 points or 0.35% lower after falling 0.25% to...

The ASX 200 made a little comeback in afternoon trade, but still traded flat on the day as local stocks struggled for direction. Energy stocks did their best to drag the broader index higher, as oil prices consolidate back above US$70/barre...

The benefit to stock prices on inclusion in the index is significant because all the ETF’s that track or try to emulate the S&P/ASX 300 must take positions and buy stock in the company.

The S&P/ASX 300 Index (ASX: XKO) is in reverse in afternoon trade today. At the time of writing, the ASX 300 is down 0.32% to 7,508 points. Let’s take a look at which ASX companies are leading the charge today. Flight Centre Travel Gr...

The clinical-stage immune-oncology company is sitting on $130 million in cash, and Bell Porter sees Imugene spending at least $30 million annually on its development program.

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

The Imugene [ASX:IMU] share price is floundering today on the back of an announcement regarding its HER-Vaxx immunotherapy in HER-2 positive gastric cancer trial. The post Imugene Share Price Sink 7% after Flagging Three New Trials (ASX:IMU...

The ASX 200 index fell today,  despite the latest Australian GDP data showing a 0.7% growth in the last quarter, beating expectations of 0.3%. The data however did not take into account the latest lockdowns, and economists are expecting a f...

HER-Vaxx is a B-cell activating immunotherapy designed to treat tumours that overexpress the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers.

ShareCafeAustralia… One Hour In… ASX200 down 58 ASX200 down 58 points (0.8%) to 7476.   BHP (-0.9%); ex div 273.56c tomorrow. Bega Cheese (-1.8%); ex div 5c,  Trading down 10c. Cardno (-1%); ex div 4c.  Trading down 1c. Carsales.com (-0.6%...

The Imugene Limited (ASX: IMU) share price is on the move on Wednesday morning. In early trade, the clinical stage immunooncology company’s shares were down 7% to 38.5 cents. The Imugene share price has now rebounded and is trading largely...

Local stocks notched up a steady day of trade on Tuesday, as global markets grind ahead in the wake of last week’s US Fed meeting. Wall Street is also pointing higher, with S&P500 futures up 0.3% in afternoon Asian trade. The ASX 200 cl...

The CAR T-cell therapy (Chimeric Antigen Receptor) has been billed as a radical new way to cure cancer. But since the US FDA approved the first cell-gene therapy to treat leukemia in 2018, the technology has not really caught on in the main...

The ASX 200 made a positive start to the week, rising by 0.22%. The mining sector was the clear winner today, rising by 3% while other sectors seesawed between gains and losses. Consumer Discretionary was the biggest drag on the broad index...

The Imugene Ltd (ASX: IMU) share price has surged more than 7% on Monday after the immuno-oncology company’s latest full-year results release. At the time of writing, the Imugene share price is trading at 37 cents apiece, up 7.25 Imugene s...

Clinical results continue to indicate that PD1-Vaxx is showing early signs of an immune response in patients, with antibodies to the target biomarker PD-1 evident in validated assays.

After three straight gains, the ASX 200 lost ground on Thursday as local markets edged lower. Last weeks iron ore-based selloff in resources has transitioned into a period of volatility on the ASX 200 Materials index, as investors assess th...

The ASX 200 closed higher on the day, but it was outpaced by the smaller end of town as the ASX microcap Emerging Companies index jumped by more than 2%. Gains were led by the ASX 200 Information Technology sector, which rose more than 1%....

Incannex lodged extensive registration form with SEC. A strategic dual-listing will give Incannex access to larger pools of capital with investors who are experienced in psychedelics and medicinal cannabis. For Incannex Healthcare (ASX:IHL)...

The clinical-stage immune-oncology company will use the funds to support work across its three novel technology platforms and bolster its clinical pipeline with acquisitions and licensing deals.

Clinical-stage pharmaceutical development company Incannex Healthcare (ASX: IHL) has filed a registration statement with the United States Securities and Exchange Commission (SEC) relating to a proposed initial public offering (IPO). The co...

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

Paul Hopper has been behind a number of successful oncology biotechs, and his latest venture is one of the few Australian companies in the radio-pharmaceuticals space. Hopper is best known for being behind Viraltyics which was bought by Mer...

The clinical-stage immune-oncology company announced it would collaborate with the NASDAQ-lister last week and has provided further information on the partnership.

The ASX 200 traded sideways today, and ended the day flat, rising just 2 points to 7,540. Financials led, rising by 1.4% following announcements from Suncorp (ASX:SUN) and NAB (ASX:NAB). Gold miners were the worst performers, as gold price...

The company is well-funded to deliver on commercial and clinical milestones including the development of CF33, PD1-Vaxx and HER-Vaxx treatments.

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a small gain. At the time of writing, the benchmark index is up 0.2% to 7,516.2 points. Four ASX shares that have failed to follow the market higher today are...

ASX 200 health stocks index (XHJ) rose by 0.23% this morning, compared to the broader index which rose by 0.11%. Micro cap medical device company dorsaVi (ASX:DVL) took the limelight this morning, jumping by 12% after saying that it has ext...

Combining Imugene’s oncolytic virus technology with Celularity’s allogeneic CAR T-cell therapy has the potential to become a novel approach to improve outcomes for patients with solid tumors.

ShareCafeAustralia… One Hour In… ASX200 down 4 ASX200 down 4 points to 7499.   Bendigo and Adelaide Bank (+0.7%); said its FY result will include a collective provision release of $19.4m, reflecting in part an improved outlook for the Aust...

The Imugene Limited (ASX: IMU) share price is pushing higher on Thursday morning. At the time of writing, the clinical stage immuno-oncology company’s shares are up 3.5% to 30.5 cents. Why is the Imugene share price rising? Investors have...

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

The ASX200 finished 0.22% lower in Tuesday trade, dragged down by a flat session for the big miners which all fell by around 1%. The ASX200 Energy index lagged the pack with a fall of 1.39%, while the major banks also struggled to find trac...

The cavalcade of life science initial public offers (IPOs) and ASX listings shows few signs of receding, with BCAL Diagnostics (ASX:BDX) last week braving the bourse amid choppy global market conditions. In the life sciences IPO Olympiad, w...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week Healthcare...

The ASX200 chalked up another day of gains in Thursday trade, and once again it was resources leading the way. The ASX200 Materials index posted a solid 1.51% gain, and has now risen by at least 1% on five of the last seven trading days. Pr...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a solid gain. At the time of writing, the benchmark index is up 0.45% to 7,413.6 points. Four ASX shares that are failing to follow the market higher today are...

Investor funds continue flowing into ASX listed biotechnology shares this year, with a total of almost $485 million of capital raised this year to date. Adding the flurry of initial public offerings (IPO) undertaken in the biotech domain,...

The biotech’s multi-million-dollar capital raise will support development opportunities across its clinical portfolio over the next four years.

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

The ASX tech sector succumbed to the latest selloff in tech equities globally. dragging the rest of the bourse down with it. The ASX 200 retreated 0.7% to close at 7,379 points while the ASX Emerging Companies Index lost 1.06%, closing at 2...

The ASX 200 touched intraday record highs, but could not hold on and closed the day just shy of its all time high. The benchmark index finished 0.46% higher at 7,428, and is now on track to finish July on a 10-month winning streak. Six out...

Securities will remain halted until Thursday, July 29, 2021, or when an announcement is released to the market.

Bell Potter is in the market raising capital for oncolytic immuno-oncology biotech Imugene, which is chaired by Viralytics’ Paul Hopper.

ShareCafeAustralia… One Hour In… ASX200 up 20 ASX200 up 20 points (+0.3%) to 7414.   BlueScope (+2.6%); cracking result.  Said 2H earnings beat guidance as all segments delivered better results than FY20.  Highest profit in 19 years. Imuge...